The ratio of 11β-hydroxysteroid dehydrogenase 1/11β-hydroxysteroid dehydrogenase 2 predicts glucocorticoid response in nasal polyps
- 33 Downloads
Glucocorticoids are the first-line medical treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), whose local metabolism is catalyzed by 11β-HSD1 and 11β-HSD2. This study investigates the role of 11β-HSD1 and 11β-HSD2 on the glucocorticoid response of CRSwNP patients and the pathogenic mechanism of these polyps.
Forty-three adult CRSwNP patients were enrolled in this study. We evaluated the endoscopic scores by a nasal polyp grading system before and after treatment. We estimated the response to glucocorticoids by the total endoscopic scores. The logistic regression models and inflammatory characteristic curves were conducted to explore the prediction of the response to glucocorticoid in CRSwNP. The expression of 11β-HSD1 and 11β-HSD2 on human sinonasal epithelial cells (HSECS) was measured under the stimulation of toll-like receptor agonists and dexamethasone.
The endoscopic scores in the CRSwNP group declined, the expression of 11β-HSD1/11β-HSD2 increased (r = 0.5276, P = 0.0011), and the cutoff value of the ratio of 11β-HSD1/11β-HSD2 was 0.4654 (sensitivity 79.17%, specificity 88.89%). Dexamethasone induced a decrease in the ratio of 11β-HSD1/11β-HSD2 (P = 0.049) by the stimulation of PGN-BS.
We found a strong correlation between the response to glucocorticoids and the ratio of 11β-HSD1/11β-HSD2, which could be used as a marker in predicting the level of tissue response to glucocorticoid therapy in CRSwNP. In addition, PGN-BS could also be a therapeutic target, as it is the negative factor that will decrease the sensitivity of glucocorticoids by reducing the ratio of 11β-HSD1/11β-HSD2.
Keywords11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2) Glucocorticoid sensitivity Nasal polyps
11β-hydroxysteroid dehydrogenase 1
11β-hydroxysteroid dehydrogenase 2
- NPA group
Nasal polyps with asthma group
- NP-SR group
Nasal polyp sensitivity with glucocorticoids group
- NP-CR group
Nasal polyp could not sensitivity with glucocorticoids group
We thank Prof. DeYun Wang for reviewing and revising the manuscript.
Natural Science Foundation of China, the Young Investigator Award, No. 81300814 for YYL. Natural Science Foundation of China, the General program project, No. 81470069 for JBS.
Compliance with ethical standards
Conflict of interest
The authors have declared that there is no conflict of interest.
- 1.Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012(23):3 (preceding table of contents, 1–298) Google Scholar
- 11.Hennebold JD, Ryu SY, Mu HH, Galbraith A, Daynes RA (1996) 11 beta-hydroxysteroid dehydrogenase modulation of glucocorticoid activities in lymphoid organs. Am J Physiol 270(2):1296–1306Google Scholar
- 18.Jun YJ, Park SJ, Kim TH, Lee SH, Lee KJ, Hwang SM et al (2014) Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in patients with chronic rhinosinusitis and their possible contribution to local glucocorticoid activation in sinus mucosa. J Allergy Clin Immunol 134(4):926–934e6CrossRefGoogle Scholar